Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of anifrolumab versus placebo in systemic sclerosis
2023-505976-31-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) comparing Anifrolumab with Placebo (2 arms). Primary endpoints: Revised-CRISS-25 response, Improvement in at least 2 Revised-CRISS-25 components and 3 more. Planned start Nov 2023; status: authorised.
02
Drugs
anifrolumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2023-505976-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505976-31-00.